These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26036539)

  • 21. Recurrent and persistent cytomegalovirus infection in a kidney recipient caused by the L595S mutation in UL97 phosphotransferase gene.
    Peixoto M; Mascarenhas L; Cunha A; Dutra M; Miranda E; Silva I; Costa S; Galvão B; Cunha A
    Antivir Ther; 2012; 17(3):585-8. PubMed ID: 22293247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
    Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
    Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Ganciclovir treatment failure in adult allogeneic hematopoietic stem cell transplant recipients with cytomegalovirus infection--a single centre experience].
    Vejražková E; Hubáček P; Kutová R; Plíšková L; Košťál M; Štěpánová V; Zavřelová A; Radocha J; Malá E; Žák P
    Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):160-8. PubMed ID: 26448304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotypic resistance of cytomegalovirus to antivirals in hematopoietic stem cell transplant recipients from Portugal: A retrospective study.
    Campos AB; Ribeiro J; Pinho Vaz C; Campilho F; Branca R; Campos A; Baldaque I; Medeiros R; Boutolleau D; Sousa H
    Antiviral Res; 2017 Feb; 138():86-92. PubMed ID: 27887982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.
    Hantz S; Garnier-Geoffroy F; Mazeron MC; Garrigue I; Merville P; Mengelle C; Rostaing L; Saint Marcoux F; Essig M; Rerolle JP; Cotin S; Germi R; Pillet S; Lebranchu Y; Turlure P; Alain S;
    J Antimicrob Chemother; 2010 Dec; 65(12):2628-40. PubMed ID: 20961907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.
    Boutolleau D; Deback C; Bressollette-Bodin C; Varnous S; Dhedin N; Barrou B; Vernant JP; Gandjbakhch I; Imbert-Marcille BM; Agut H
    Antiviral Res; 2009 Feb; 81(2):174-9. PubMed ID: 19063923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
    Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
    Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
    Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
    J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
    Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
    Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
    Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
    López-Medrano F; Rueda B; Lizasoain M; Juan RS; Folgueira D; Andrés A; Morales JM; Jiménez C; Meneu JC; Aguado JM
    Transpl Infect Dis; 2009 Oct; 11(5):400-4. PubMed ID: 19570139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience.
    Paudice N; Mehmetaj A; Zanazzi M; Moscarelli L; Piperno R; Di Maria L; Bertoni E; Salvadori M
    Transplant Proc; 2009 May; 41(4):1204-6. PubMed ID: 19460517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
    Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
    Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
    Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mutations in the
    Demin MV; Tikhomirov DS; Biderman BV; Drokov MY; Sudarikov AB; Tupoleva TA; Filatov FP
    Vopr Virusol; 2022 Mar; 67(1):37-47. PubMed ID: 35293187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human cytomegalovirus (CMV) UL97 D605E mutation has a higher prevalence in infants with primary CMV infection compared with transplant recipients with CMV recurrence.
    Sun J; Cao G; Zhang L; Zhang Y; Zhao Z; Hu J; Ji Y
    Transplant Proc; 2012 Dec; 44(10):3022-5. PubMed ID: 23195018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients.
    Ozaki KS; Câmara NO; Nogueira E; Pereira MG; Granato C; Melaragno C; Camargo LF; Pacheco-Silva A
    Clin Transplant; 2007; 21(5):675-80. PubMed ID: 17845644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis.
    Boivin G; Goyette N; Farhan M; Ives J; Elston R
    J Clin Virol; 2012 Mar; 53(3):208-13. PubMed ID: 22237003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Investigation of Ganciclovir Resistance in Cytomegalovirus Isolates by Phenotypic and Genotypic Methods].
    Sarınoğlu RC; Çolak D; Küpesiz OA; Kuşkucu MA; Yalçın K; Sağlık İ; Mutlu D; Midilli K; Peker BO; Özhak B; Özkul A; Foldes K
    Mikrobiyol Bul; 2023 Jul; 57(3):401-418. PubMed ID: 37462304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.